Market Performance of Inmune Bio and Peer Comparison

During the 24‑hour period concluding at 01:12 AM Central European Time on Saturday, 24 April 2026, Inmune Bio Inc. (ticker INMB) experienced a modest upward movement of 0.63 %. At the close, the stock traded at US $1.46 on major exchanges. With a free‑float of 27.8 million shares, the company’s market capitalization stands at US $44.7 million, reflecting a cumulative 25.46 % decline from the previous month‑end valuation.

The liquidity of the shares is relatively limited, as evidenced by a total trading volume of roughly US $370.3 thousand over the preceding 24 hours. This figure underscores the modest interest from institutional and retail investors in the near‑term. Over a longer horizon, the 200‑day simple moving average is positioned at US $1.64, suggesting that the current price sits slightly below the medium‑term trend.

Historical extremes illustrate the volatility that has accompanied the stock’s trajectory. The 52‑week high of US $2.60 was reached on 8 September 2026, while the 52‑week low of US $1.09 occurred on 31 March 2026. These bounds provide context for potential support and resistance levels as the market continues to digest the company’s recent developments.

Peer Activity in the Last 24 Hours

  • Momentus (MNTS) closed up 2.13 % at US $2.15, with a market cap of US $52.7 million.
  • Airgain (AIRG) recorded a -1.23 % decline, trading at US $4.05 and a market capitalization of US $53.3 million.
  • Clene (CLNN) saw a modest 0.8 % increase, priced at US $3.88 and a market cap of US $53.4 million.
  • Travelzoo (TZOO) experienced a -2.86 % drop, with a price of US $5.07 and a market cap of US $53.5 million; its price‑earnings ratio stands at 159.13.
  • Leonabio (LONA) surged 7.59 %, trading at US $4.84 and a market cap of US $53.4 million.

These contemporaneous movements illustrate a mixed environment for mid‑cap biotech and technology stocks, with several peers benefiting from recent catalysts while others remain under pressure.

Company Overview

Inmune Bio Inc., headquartered in La Jolla, California, is a clinical‑stage biotechnology enterprise focused on the development of therapeutic agents for oncology indications. The firm serves the United States market exclusively and is listed on the Nasdaq stock exchange. Its initial public offering was conducted on 4 February 2019. For detailed information on the company’s pipeline, regulatory milestones, and corporate governance, prospective investors may consult the official website at www.inmunebio.com .

This article provides a concise snapshot of Inmune Bio’s recent trading activity, contextualized by peer performance and key financial metrics. The information is intended for investors and market participants seeking an updated understanding of the company’s position within the broader biotech sector.